FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199211208> ?p ?o ?g. }

• W3199211208 endingPage "5464" @default.
• W3199211208 startingPage "5452" @default.
• W3199211208 abstract "In the absence of head-to-head trials, we performed an indirect treatment comparison of the β3-adrenergic agonists vibegron and mirabegron in the treatment of overactive bladder (OAB). PubMed, Embase, and Cochrane Library were searched for articles related to phase 3, double-blind, controlled trials of vibegron 75 mg and mirabegron 25/50 mg in patients with OAB. Efficacy outcomes included change from baseline at weeks 4, 12, and 52 in mean daily number of total urinary incontinence episodes and micturitions and mean volume voided/micturition. Effect size was computed as placebo-subtracted change from baseline (weeks 4, 12) or active control (tolterodine)-subtracted change from baseline (week 52) for each treatment group. Adverse events (AEs) are presented descriptively. After removal of duplicates, 49 records were identified, and after screening 9 met inclusion criteria for analysis. Vibegron showed significantly greater reduction in mean daily number of total incontinence episodes than mirabegron 25 mg at week 4, mirabegron 50 mg (weeks 4, 52), and tolterodine (weeks 4, 12) (P < 0.05, each) and significantly greater improvement in volume voided versus mirabegron 25 mg (week 12), mirabegron 50 mg (weeks 12, 52), and tolterodine (week 4) (P < 0.05, each). Confidence intervals of point estimates overlapped zero for all other comparisons of vibegron and mirabegron (25 or 50 mg) or tolterodine, indicating no significant differences between treatments for these time/endpoints. Urinary tract infection, hypertension, and dry mouth were the most commonly occurring AEs for vibegron, mirabegron, and tolterodine, respectively, in the short-term trials; hypertension was the most commonly occurring AE with all three treatments in the long-term trials. Vibegron was associated with significant improvement in total incontinence episodes versus mirabegron at 4 and 52 weeks and volume voided at 12 and 52 weeks. Improvement in micturitions was similar between vibegron and mirabegron or tolterodine. Incidence of AEs was generally comparable between vibegron and mirabegron." @default.
• W3199211208 created "2021-09-27" @default.
• W3199211208 creator A5008846974 @default.
• W3199211208 creator A5035835916 @default.
• W3199211208 creator A5050118503 @default.
• W3199211208 creator A5063860743 @default.
• W3199211208 creator A5078893992 @default.
• W3199211208 creator A5079115002 @default.
• W3199211208 date "2021-09-18" @default.
• W3199211208 modified "2023-10-13" @default.
• W3199211208 title "Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison" @default.
• W3199211208 cites W1534986865 @default.
• W3199211208 cites W1579782291 @default.
• W3199211208 cites W1605716039 @default.
• W3199211208 cites W1972477468 @default.
• W3199211208 cites W2002743872 @default.
• W3199211208 cites W2005947177 @default.
• W3199211208 cites W2038660377 @default.
• W3199211208 cites W2067945145 @default.
• W3199211208 cites W2082897746 @default.
• W3199211208 cites W2089635159 @default.
• W3199211208 cites W2107806473 @default.
• W3199211208 cites W2110991424 @default.
• W3199211208 cites W2164958589 @default.
• W3199211208 cites W2169016904 @default.
• W3199211208 cites W2606250578 @default.
• W3199211208 cites W2800933213 @default.
• W3199211208 cites W2805086678 @default.
• W3199211208 cites W2944264319 @default.
• W3199211208 cites W3008491230 @default.
• W3199211208 cites W3094049274 @default.
• W3199211208 cites W3099293749 @default.
• W3199211208 cites W3116040369 @default.
• W3199211208 cites W4213351464 @default.
• W3199211208 cites W4280598406 @default.
• W3199211208 doi "https://doi.org/10.1007/s12325-021-01902-8" @default.
• W3199211208 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8520873" @default.
• W3199211208 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34537953" @default.
• W3199211208 hasPublicationYear "2021" @default.
• W3199211208 type Work @default.
• W3199211208 sameAs 3199211208 @default.
• W3199211208 citedByCount "14" @default.
• W3199211208 countsByYear W31992112082020 @default.
• W3199211208 countsByYear W31992112082021 @default.
• W3199211208 countsByYear W31992112082022 @default.
• W3199211208 countsByYear W31992112082023 @default.
• W3199211208 crossrefType "journal-article" @default.
• W3199211208 hasAuthorship W3199211208A5008846974 @default.
• W3199211208 hasAuthorship W3199211208A5035835916 @default.
• W3199211208 hasAuthorship W3199211208A5050118503 @default.
• W3199211208 hasAuthorship W3199211208A5063860743 @default.
• W3199211208 hasAuthorship W3199211208A5078893992 @default.
• W3199211208 hasAuthorship W3199211208A5079115002 @default.
• W3199211208 hasBestOaLocation W31992112081 @default.
• W3199211208 hasConcept C126322002 @default.
• W3199211208 hasConcept C126894567 @default.
• W3199211208 hasConcept C142724271 @default.
• W3199211208 hasConcept C175768497 @default.
• W3199211208 hasConcept C197934379 @default.
• W3199211208 hasConcept C204787440 @default.
• W3199211208 hasConcept C27081682 @default.
• W3199211208 hasConcept C2778164427 @default.
• W3199211208 hasConcept C2778941218 @default.
• W3199211208 hasConcept C2781020410 @default.
• W3199211208 hasConcept C71924100 @default.
• W3199211208 hasConcept C77411442 @default.
• W3199211208 hasConceptScore W3199211208C126322002 @default.
• W3199211208 hasConceptScore W3199211208C126894567 @default.
• W3199211208 hasConceptScore W3199211208C142724271 @default.
• W3199211208 hasConceptScore W3199211208C175768497 @default.
• W3199211208 hasConceptScore W3199211208C197934379 @default.
• W3199211208 hasConceptScore W3199211208C204787440 @default.
• W3199211208 hasConceptScore W3199211208C27081682 @default.
• W3199211208 hasConceptScore W3199211208C2778164427 @default.
• W3199211208 hasConceptScore W3199211208C2778941218 @default.
• W3199211208 hasConceptScore W3199211208C2781020410 @default.
• W3199211208 hasConceptScore W3199211208C71924100 @default.
• W3199211208 hasConceptScore W3199211208C77411442 @default.
• W3199211208 hasIssue "11" @default.
• W3199211208 hasLocation W31992112081 @default.
• W3199211208 hasLocation W31992112082 @default.
• W3199211208 hasLocation W31992112083 @default.
• W3199211208 hasLocation W31992112084 @default.
• W3199211208 hasOpenAccess W3199211208 @default.
• W3199211208 hasPrimaryLocation W31992112081 @default.
• W3199211208 hasRelatedWork W1971608743 @default.
• W3199211208 hasRelatedWork W2082897746 @default.
• W3199211208 hasRelatedWork W2084274868 @default.
• W3199211208 hasRelatedWork W2095517557 @default.
• W3199211208 hasRelatedWork W2605473068 @default.
• W3199211208 hasRelatedWork W2606611151 @default.
• W3199211208 hasRelatedWork W2613863892 @default.
• W3199211208 hasRelatedWork W3129776390 @default.
• W3199211208 hasRelatedWork W3199211208 @default.
• W3199211208 hasRelatedWork W4206166447 @default.
• W3199211208 hasVolume "38" @default.
• W3199211208 isParatext "false" @default.
• W3199211208 isRetracted "false" @default.

• next